Eppendorf continues on course for growth
- Sustained sales growth
- Increased market share in Asia
- Sales before earnings and taxes up by 20.1 %
In the Life Science markets conditions improved with the economic recovery in the Financial Year 2010. While many companies made up their losses from the previous year which were due to the economic crisis, Eppendorf was able to consolidate its market position again during the reporting year. Eppendorf achieved a continued positive development of its performance.
(firmenpresse) - The sales of the Eppendorf group increased to 484 million Euros in 2010, surpassing sales in the previous year by 11.7 percent (433,2 million Euros in the previous year).
International growth was mixed in the reporting year. While Asia showed the strongest growth with 19.9 percent, North America grew by 10.9 percent and, Europe exceeded previous year's sales by 8.4 percent.
There was a pleasant increase in earnings before interest and taxes by 20.1 percent from 77.9 million to 93.6 million Euros. The profit margin increased from 18.0 percent in 2009 to 19.4 percent in the reporting period. Annual profits were up by 20.8 percent and reached 59.3 million Euros (49.1 million Euros in the previous year).
The financial statement of the Eppendorf group confirms its extremely solid structure of the previous years and shows yet another improvement with an equity ratio of more than 58 percent in 2010 (55.3 percent in the previous year).
At the end of 2010, the Eppendorf group employed a total of 2622 people (2502 employees in the previous year).
"After the upheaval of the economic crisis of 2009 the economy was not yet back on solid footing in 2010. In spite of this, Eppendorf can look back on a successful year based on strong growth in Asia and the recovery of the European and US economies", comments Klaus Fink, CEO of Eppendorf AG who will swap the Chair of the Executive Board with the Chair of the Supervisory Board on May 1, 2011. On the same day, Dr. Dirk Ehlers will succeed him as CEO.
Eppendorf has an optimistic outlook for the future and expects a positive development in the current financial year 2011, with further growth in sales and earnings.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Eppendorf is a biotech company which develops, produces and distributes systems for use in all spheres of life science. The company's broad range of high quality products and systems is used by researchers worldwide to efficiently carry out their work.
The product range includes pipettes, dispensers and centrifuges as well as consumables such as micro test tubes and pipette tips. In addition to this, Eppendorf provides instruments and systems for automated liquid handling. Even a complete range of devices for DNA amplification for standard PCR or real-time PCR as well as systems for cell manipulation and electroporation are available. New Brunswick Scientific, Edison, USA, stands for expertise and top products within the Eppendorf Group in the field of cell growth, detection and storage.
Eppendorf products are designed for academic and commercial research facilities, but also for industrial companies in the field of biotechnology and in other sectors using biotech research processes. Innovative research approaches will call for miniature applications with an increased sample throughput for future diagnostics and therapy. This implies a trend towards automation and a level of reproducibility for which the company's high level of technology and expertise will be sought after on the market.
Eppendorf is represented in all important markets worldwide. Although the company is placing main emphasis on North America as the regional market, Asia has a high potential with dynamic rates of growth.
Eppendorf was founded in Hamburg in 1945 and has more than 2500 employees worldwide. The company has subsidiaries in 18 countries and is represented in many other markets by distributors.
Eppendorf AG
Bettina Doerler
public relations officer
doerler.b(at)eppendorf.de
+49 40 538 01-640
Datum: 09.06.2011 - 09:40 Uhr
Sprache: Deutsch
News-ID 1024019
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Pharmaceuticals & Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eppendorf continues on course for growth
"
steht unter der journalistisch-redaktionellen Verantwortung von
Eppendorf AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
